UroGen Pharma Ltd. (URGN) NASDAQ

26.76

+0.22(+0.83%)

Updated at June 03 01:09PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Elizabeth A. Barrett	President, Chief Executive Officer & Director	2.19M	1962
Christopher Degnan	Chief Financial Officer	561,797	1980
Ron Bentsur	Advisor	699,766	1966
Mark Schoenberg	Chief Medical Officer	730,240	1958
Jason Drew Smith	General Counsel, Chief Compliance Officer & Corporate Secretary	978,418	1972
Michael J. Louie	Chief Development Officer	0	N/A
Timothy Simon	Senior Vice President of Business Development & Portfolio Strategy	0	N/A
Alison Hardgrove	Senior Vice President of Human Resources	0	N/A
James Ottinger	Executive Vice President of Regulatory Affairs & Quality	0	N/A
Vincent I. Perrone	Senior Director of Investor Relations	0	N/A
Marina Konorty	Executive Vice President of Research & Development and Technical Operations	0	N/A
Bryon Wornson	Executive Vice President of Talent, Advocacy & Communications	0	N/A
David Lin	Chief Commercial Officer	0	N/A

Name

Title

Pay

Year Born

Elizabeth A. Barrett

President, Chief Executive Officer & Director

2.19M

1962

Christopher Degnan

Chief Financial Officer

561,797

1980

Ron Bentsur

Advisor

699,766

1966

Mark Schoenberg

Chief Medical Officer

730,240

1958

Jason Drew Smith

General Counsel, Chief Compliance Officer & Corporate Secretary

978,418

1972

Michael J. Louie

Chief Development Officer

N/A

Timothy Simon

Senior Vice President of Business Development & Portfolio Strategy

N/A

Alison Hardgrove

Senior Vice President of Human Resources

N/A

James Ottinger

Executive Vice President of Regulatory Affairs & Quality

N/A

Vincent I. Perrone

Senior Director of Investor Relations

N/A

Marina Konorty

Executive Vice President of Research & Development and Technical Operations

N/A

Bryon Wornson

Executive Vice President of Talent, Advocacy & Communications

N/A

David Lin

Chief Commercial Officer

N/A

Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.